<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirteen cases, including 10 relapse cases, of refractory <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (aged 17-70, median 46) by <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (Ara-C) combined with granulocyte colony-stimulating factor (G-CSF) simultaneously to enhance the sensitivity to Ara-C </plain></SENT>
<SENT sid="1" pm="."><plain>Low dose Ara-C (10-40 mg/day) combined with G-CSF was administered in most of them </plain></SENT>
<SENT sid="2" pm="."><plain>Complete (CR) and partial remission (PR) were achieved in 5 and 4 patients, respectively, and response (CR + PR) rate was 69.2% </plain></SENT>
<SENT sid="3" pm="."><plain>We obtained 5 CRs and 3 PRs in 10 patients with relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>However, CR and PR duration was short in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="5" pm="."><plain>None of the 3 patients with MO, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformed from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with trilineage <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (TMDS) had any response </plain></SENT>
<SENT sid="6" pm="."><plain>There was no leukemic colony formation in the culture medium containing G-CSF in the nonresponding patients </plain></SENT>
<SENT sid="7" pm="."><plain>The combination therapy caused severe <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e>, and most patients experienced prolonged <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, and suffered from <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In some patients enhanced chemosensitivity of leukemic cells induced by G-CSF was indicated but, the effect of this approach must be determined by large scale controlled studies </plain></SENT>
</text></document>